Abstract: There is provided a monitoring system for remotely monitoring an item or activity, the monitoring system including a recording device for recording a visual record of the item, a communicator for communicating the visual record, and a security device for controlling access to the monitoring system. Also provided is a method of remotely monitoring an item by recording a digital image of the item, communicating the digital image of the item through a communication system, and accessing the digital image using a secured access device.
Type:
Grant
Filed:
October 16, 2002
Date of Patent:
December 19, 2006
Assignee:
See Progress, Inc.
Inventors:
David Henderson, Gordon Henderson, Jerry Henderson
Abstract: A compound for use as a therapeutic or diagnostic radiopharmaceutical includes a group capable of complexing a medically useful metal attached to a moiety which is capable of binding to a gastrin releasing peptide receptor. A method for treating a subject having a neoplastic disease includes administering to the subject an effective amount of a radiopharmaceutical having a metal chelated with a chelating group attached to a moiety capable of binding to a gastrin releasing peptide receptor expressed on tumor cells with subsequent internalization inside of the cell. A method of forming a therapeutic or diagnostic compound includes reacting a metal synthon with a chelating group covalently linked with a moiety capable of binding a gastrin releasing peptide receptor.
Type:
Grant
Filed:
December 29, 2004
Date of Patent:
December 12, 2006
Assignee:
Curators of the University of Missouri
Inventors:
Timothy J. Hoffman, Wynn A. Volkert, Ning Li, Gary Sieckman, Chrys-Ann Higginbotham
Abstract: A monolithic bioresorbable implant includes optimally designed openings to treat tissue disorders or drug delivery. Preferably, the implant is made from calcium salts. A method of filling a recipient treatment site includes the step of disposing the monolithic bioresorbable implant into the site.
Abstract: There is provided a method of promoting neurogenesis by administering a therapeutic amount of a nitric oxide donor compound to a patient in need of neurogenesis promotion. Also provided is a compound for providing neurogenesis having an effective amount of a nitric oxide donor sufficient to promote neurogenesis. A nitric oxide compound for promoting neurogenesis is also provided. Further, a method of augmenting the production of brain cells and facilitating cellular structural and receptor changes by administering an effective amount of a nitric oxide donor compound to a site in need of augmentation is provided. There is provided method of increasing both neurological and cognitive function by administering an effective amount of a nitric oxide donor compound to a patient.
Abstract: A method and kit of diagnosing endometriosis in a female patient suspected of having endometriosis. The method includes obtaining a sample from the patient. The sample is analyzed to detect the presence of a purified and isolated endometriotic haptoglobin designated ENDO-I and functional analogs thereof. A therapeutic for treating endometriosis by modulating the expression of a purified and isolated endometriotic haptoglobin designated ENDO-I and functional analogs thereof and a pharmaceutically acceptable carrier.
Type:
Grant
Filed:
November 27, 2002
Date of Patent:
October 17, 2006
Assignee:
The Curators of the University of Missouri
Abstract: A new group of picornaviruses is disclosed. The picornaviruses of the invention comprise in the non-coding region of their viral genome a nucleotide sequence which corresponds to cDNA sequence (I) or homologous sequences having at least 75% homology to the SEQ ID NO:1, and they cause mammalian disease. Further aspects of the invention comprise a protein corresponding to a protein of the picornaviruses, antiserum or antibody directed against a protein of the picornaviruses, antigen comprising a protein of the picornaviruses, diagnostic kits, vaccines, use of the picornaviruses in medicaments, particularly for the treatment or prevention of Myocarditis, Cardiomyopathia, Guillain Barré Syndrome, and Diabetes Mellitus, Multiple Sclerosis, Chronic Fatique Syndrome, Myasthenia Gravis, Amyothrophic Lateral Sclerosis, Dermatomyositis, Polymyositis, Spontaneous Abortion, and Sudden Infant Death Syndrome, and methods of treatment of diseases caused by the picornaviruses.
Abstract: An isolated and purified ?-N-acetyl-D-galactosaminidase from Clostridium perfringens and homologs thereof are disclosed. A method for purifying and isolating the ?-N-acetylgalactosaminidase from Clostridium perfringens by removing neuramidases is disclosed. A process for using the ?-N-acetylgalactosaminidase from Clostridium perfringens in altering type A blood cells to type O blood cells is disclosed. A process for altering cells expressing blood group A epitope by using ?-N-acetylgalactosaminidase isolated from Clostridium perfringens in altering the cells expressing blood group A epitope to cells expressing blood group O epitope is disclosed.
Type:
Grant
Filed:
January 29, 2002
Date of Patent:
July 11, 2006
Assignee:
The Curators of the University of Missouri
Abstract: The present invention relates to the use of heat shock proteins to enhance production of one or more chemokines by a cell. The present invention also relates to the use of a heat shock protein in the treatment or prophylaxis of an infectious disease. The present invention also relates to a peptide from an extracellular domain of CCR5 and the use of the peptide in the treatment or prophylaxis of an infectious disease.
Type:
Grant
Filed:
December 21, 2000
Date of Patent:
July 4, 2006
Inventors:
Thomas Lehner, Charles George Kelly, Yufei Wang
Abstract: The invention relates to antibodies recognizing acetylcholinesterase or a C-terminal peptide derived from acetyl-cholinesterase, useful in diagnosing central nervous system (CNS) stress, elevated glucocorticoid level, disruption of the blood-brain barrier or Alzheimer's disease. The invention also relates to methods for the diagnosis of central nervous system (CNS) stress, elevated glucocorticoid level or disruption of the blood-brain barrier in a mammal, by use of the antibodies of the invention.
Type:
Grant
Filed:
May 31, 2000
Date of Patent:
June 20, 2006
Assignee:
Yissum Research Development Company of the Hebrew University of Jerusalem
Abstract: A compound for use as a therapeutic or diagnostic radiopharmaceutical includes a group capable of complexing a medically useful metal attached to a moiety which is capable of binding to a gastrin releasing peptide receptor. A method for treating a subject having a neoplastic disease includes administering to the subject an effective amount of a radiopharmaceutical having a metal chelated with a chelating group attached to a-moiety capable of binding to a gastrin releasing peptide receptor expressed on tumor cells with subsequent internalization inside of the cell. A method of forming a therapeutic or diagnostic compound includes reacting a metal synthon with a chelating group covalently linked with a moiety capable of binding a gastrin releasing peptide receptor.
Type:
Grant
Filed:
May 2, 2001
Date of Patent:
June 13, 2006
Assignee:
The Curators of the University of Missouri
Inventors:
Timothy J. Hoffman, Wynn A. Volkert, Gary Sieckman, Charles J. Smith, Hariprasad Gali
Abstract: The present invention relates generally to therapeutic compositions for the treatment and/or prophylaxis of intestinal disease conditions in animals and birds caused or exacerbated by Lawsonia intracellularis or similar or otherwise related microorganism. In particular, the present invention provides a novel gene derived from Lawsonia intracellularis which encodes an immunogenic OmpH peptide, polypeptide or protein that is particularly useful as an antigen in vaccine preparation for conferring humoral immunity against Lawsonia intracellularis and related pathogens in animal hosts. The present invention is also directed to methods for the treatment and/or prophylaxis of such intestinal disease conditions and to diagnostic agents and procedures for detecting Lawsonia intracellularis or similar or otherwise related microorganisms.
Type:
Grant
Filed:
May 11, 2000
Date of Patent:
May 30, 2006
Assignees:
Agriculture Victoria Services PTY LTD, Pig Research and Development Corp.
Inventors:
Detlef Hasse, Michael Panaccio, Meri Sinistaj
Abstract: There is provided a method for identifying pre-malignancy, malignancy, and degree of pre-malignancy and malignancy of a cell by detecting extrachromosomal and intrachromosomal gene amplification. Also provided is a marker for the identification of pre-malignancy, malignancy, and degree of pre-malignancy and malignancy of a cell containing extrachromosomal and intrachromosomal gene amplification of a gene. A diagnostic tool for the diagnosis and prognosis or cervical cancer containing extrachromosomal and intrachromosomal gene amplification of a gene.
Type:
Grant
Filed:
January 22, 2001
Date of Patent:
May 16, 2006
Assignees:
University of Manitoba, Cancercare Manitoba
Abstract: The present invention relates generally to therapeutic compositions for the treatment and/or prophylaxis of intestinal disease conditions in animals and birds caused or exacerbated by Lawsonia intracellularis or similar or otherwise related microorganism. In particular, the present invention provides a novel gene derived from Lawsonia intracellularis which encodes an immunogenic hemolysin peptide, polypeptide or protein that is particularly useful as an antigen in vaccine preparation for conferring humoral immunity against Lawsonia intracellularis and related pathogens in animal hosts. The present invention is also directed to methods for the treatment and/or prophylaxis of such intestinal disease conditions and to diagnostic agents and procedures for detecting Lawsonia intracellularis or similar or otherwise related microorganisms.
Type:
Grant
Filed:
May 11, 2000
Date of Patent:
April 18, 2006
Assignees:
Pfizer Products, Inc., Agriculture Victoria Services Pty. Ltd., Pig Research and Development Corporation
Inventors:
Michael Panaccio, Everett Lee Rosey, Detlef Hasse, Robert Gerard Ankenbauer
Abstract: According to the present invention, there is provided a transverse connector having a seat rod for seating a rod therein engagement mechanism including a rod engagement seat forming a portion of the rod seat, the engagement mechanism being movable into and out of engagement with the rod seated in the rod seat.
Abstract: An emulsion for preparing a low-conductivity surface for powder coating, the emulsion including an emulsified organofunctional silane solution. A pre-powder coating emulsion provides a surface with conductivity. A non-conductive object having applied to an exterior surface of the object the emulsion including an emulsified organofunctional silane solution.
Abstract: There is provided a complex for use as a therapeutic pharmaceutical, the complex has a ligand containing at least one hydroxyalkyl phosphine donor group bound to a gold atom to form a stable gold-ligand complex. Also provided is a method of treating cancer by administering an effective amount of a complex having a ligand of at least one hydroxyalkyl phosphine group bound to a gold atom to form a stable gold-ligand complex. Also provided is a method of preventing the metastasis of cancer and arresting cell growth by administering an effective amount of a complex having a ligand of at least one hydroxyalkyl phosphine group bound to a gold atom to form a stable gold-ligand complex.
Type:
Grant
Filed:
June 23, 2000
Date of Patent:
January 24, 2006
Assignee:
The Curators of the University of Missouri
Inventors:
Kattesh V. Katti, Wynn A. Volkert, Timothy Hoffman
Abstract: Isolated polynucleotide molecules contain a nucleotide sequence that encodes a L. intracellularis HtrA, PonA, HypC, LysS, YcfW, ABC1, or Omp100 protein, a substantial portion of the sequences, or a homologous sequence. Related polypeptides, immunogenic compositions and assays are described.
Abstract: This invention relates to stabilized protein compositions, methods for preparing such stabilized protein compositions, dosage forms for administering such stabilized protein compositions to mammals and methods for preventing or treating infections in mammals by administering such protein compositions to mammals. More particularly, the stabilized protein compositions of the present invention contain therapeutically effective amounts of G-CSF, such as bovine G-CSF, in combination with a stabilizing buffer, such as HEPES, TES or TRICINE, for treating and preventing infections, including mastitis, in cattle.
Type:
Grant
Filed:
August 12, 1999
Date of Patent:
December 27, 2005
Assignees:
Pfizer Inc., Pfizer Products Inc.
Inventors:
Peter C. Canning, Barbara J. Kamicker, Kasra Kasraian
Abstract: A method for overcoming mild to moderate immune suppression includes the steps of inducing production of naïve T-cells and restoring T-cell immunity. A method of vaccine immunotherapy includes the steps of inducing production of naïve T-cells and exposing the naïve T-cells to endogenous or exogenous antigens at an appropriate site. Additionally, a method for unblocking immunization at a regional lymph node includes the steps of promoting differentiation and maturation of immature dendritic cells at a regional lymph node and allowing presentation of processed peptides by resulting mature dendritic cells, thus, for example, exposing tumor peptides to T-cells to gain immunization of the T-cells. Further, a method of treating cancer and other persistent lesions includes the steps of administering an effective amount of a natural cytokine mixture as an adjuvant to endogenous or exogenous administered antigen to the cancer or other persistent lesions.